XORTX Therapeutics Inc. (XRTX), Wednesday announced that the company has an upcoming Type B meeting with the US Food and Drug Administration regarding its XRx-026 program for the treatment of gout.
The XRx-026 program is developing XORLO, a proprietary formulation of oxypurinol to treat individuals suffering from gout, an inflammatory arthritis.
The purpose of this meeting will be to review the XRx-026 program and its readiness for submission of a New Drug Application to gain marketing approval for XORLOTM in the US using the FDA 505(b)2 development pathway.
The company stated that it will submit a type B meeting package to the FDA during the next week, with FDA communications expected by April 26, 2025.
The Type B meeting review will include review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence regarding XRx-026 program.
Currently, XORTX's stock is moving up 5.78 percent, to $1.005 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.